Cargando…
Major clinical research advances in gynecologic cancer in 2019
In 2019, 12 topics were selected as the major research advances in gynecologic oncology. Herein, we first opted to introduce the significant clinical activity of pembrolizumab in women with advanced cervical cancer based on the results of the phase 2 KEYNOTE-158 trial. Thereafter, we reviewed 5 topi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189081/ https://www.ncbi.nlm.nih.gov/pubmed/32319232 http://dx.doi.org/10.3802/jgo.2020.31.e48 |
_version_ | 1783527434731126784 |
---|---|
author | Kim, Miseon Suh, Dong Hoon Lee, Kyung-Hun Eom, Keun-Yong Lee, Jung-Yun Lee, Yoo-Young Hansen, Hanne Falk Mirza, Mansoor Raza Kim, Jae-Weon |
author_facet | Kim, Miseon Suh, Dong Hoon Lee, Kyung-Hun Eom, Keun-Yong Lee, Jung-Yun Lee, Yoo-Young Hansen, Hanne Falk Mirza, Mansoor Raza Kim, Jae-Weon |
author_sort | Kim, Miseon |
collection | PubMed |
description | In 2019, 12 topics were selected as the major research advances in gynecologic oncology. Herein, we first opted to introduce the significant clinical activity of pembrolizumab in women with advanced cervical cancer based on the results of the phase 2 KEYNOTE-158 trial. Thereafter, we reviewed 5 topics, including systemic lymphadenectomy in the advanced stage with no gross residual tumor, secondary cytoreductive surgery in recurrent ovarian cancer according to the results of Gynecologic Oncology Group-213 trial, dose-dense weekly paclitaxel scheduling as first-line chemotherapy, the utility of intraperitoneal therapy in the advanced stage, and an update on poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Additionally, we conducted a thorough review of emerging data from several clinical trials on PARP inhibitors according to drug, target population, and combined usage. For uterine corpus cancer, we reviewed adjuvant therapy for high-risk disease and chemotherapy in advanced/recurrent disease. For the field of radiation oncology, we discussed the utility of neoadjuvant chemotherapy added to chemoradiotherapy and the treatment of radiation-induced cystitis using hyperbaric oxygen. Finally, we discussed the use of individualized therapy with humanized monoclonal antibodies (trastuzumab emtansine and sacituzumab govitecan-hziy) and combination therapy (fulvestrant plus alpesilib, fulvestrant plus anastrozole, and ribociclib plus endocrine therapy) for women with advanced breast cancer. |
format | Online Article Text |
id | pubmed-7189081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-71890812020-05-07 Major clinical research advances in gynecologic cancer in 2019 Kim, Miseon Suh, Dong Hoon Lee, Kyung-Hun Eom, Keun-Yong Lee, Jung-Yun Lee, Yoo-Young Hansen, Hanne Falk Mirza, Mansoor Raza Kim, Jae-Weon J Gynecol Oncol Review Article In 2019, 12 topics were selected as the major research advances in gynecologic oncology. Herein, we first opted to introduce the significant clinical activity of pembrolizumab in women with advanced cervical cancer based on the results of the phase 2 KEYNOTE-158 trial. Thereafter, we reviewed 5 topics, including systemic lymphadenectomy in the advanced stage with no gross residual tumor, secondary cytoreductive surgery in recurrent ovarian cancer according to the results of Gynecologic Oncology Group-213 trial, dose-dense weekly paclitaxel scheduling as first-line chemotherapy, the utility of intraperitoneal therapy in the advanced stage, and an update on poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Additionally, we conducted a thorough review of emerging data from several clinical trials on PARP inhibitors according to drug, target population, and combined usage. For uterine corpus cancer, we reviewed adjuvant therapy for high-risk disease and chemotherapy in advanced/recurrent disease. For the field of radiation oncology, we discussed the utility of neoadjuvant chemotherapy added to chemoradiotherapy and the treatment of radiation-induced cystitis using hyperbaric oxygen. Finally, we discussed the use of individualized therapy with humanized monoclonal antibodies (trastuzumab emtansine and sacituzumab govitecan-hziy) and combination therapy (fulvestrant plus alpesilib, fulvestrant plus anastrozole, and ribociclib plus endocrine therapy) for women with advanced breast cancer. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2020-04-20 /pmc/articles/PMC7189081/ /pubmed/32319232 http://dx.doi.org/10.3802/jgo.2020.31.e48 Text en Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kim, Miseon Suh, Dong Hoon Lee, Kyung-Hun Eom, Keun-Yong Lee, Jung-Yun Lee, Yoo-Young Hansen, Hanne Falk Mirza, Mansoor Raza Kim, Jae-Weon Major clinical research advances in gynecologic cancer in 2019 |
title | Major clinical research advances in gynecologic cancer in 2019 |
title_full | Major clinical research advances in gynecologic cancer in 2019 |
title_fullStr | Major clinical research advances in gynecologic cancer in 2019 |
title_full_unstemmed | Major clinical research advances in gynecologic cancer in 2019 |
title_short | Major clinical research advances in gynecologic cancer in 2019 |
title_sort | major clinical research advances in gynecologic cancer in 2019 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189081/ https://www.ncbi.nlm.nih.gov/pubmed/32319232 http://dx.doi.org/10.3802/jgo.2020.31.e48 |
work_keys_str_mv | AT kimmiseon majorclinicalresearchadvancesingynecologiccancerin2019 AT suhdonghoon majorclinicalresearchadvancesingynecologiccancerin2019 AT leekyunghun majorclinicalresearchadvancesingynecologiccancerin2019 AT eomkeunyong majorclinicalresearchadvancesingynecologiccancerin2019 AT leejungyun majorclinicalresearchadvancesingynecologiccancerin2019 AT leeyooyoung majorclinicalresearchadvancesingynecologiccancerin2019 AT hansenhannefalk majorclinicalresearchadvancesingynecologiccancerin2019 AT mirzamansoorraza majorclinicalresearchadvancesingynecologiccancerin2019 AT kimjaeweon majorclinicalresearchadvancesingynecologiccancerin2019 |